Okay.

Um, most of our systems are able to build in anticoagulation prophylaxis.

That's now just automatically ordered when we put in the Ami-Laz regimen for us.

Um, if it's not, that certainly has to be on your radar.

Uh, but coming out of the gates with amivantamab, infusion-related reactions, DVT, PE, and derm toxicity were the big three.

Well, now that we can build the anticoagulation into our regimens, we have our subcutaneous formulation that can really cut down on in-infusion related reactions, and doing the dex pre-meds two days before significantly, uh, limits it even further.

It really hones into that dermatologic toxicity.

Now, if this rash for this particular patient was still, despite those efforts of prophylactic measures, still continues to worsen or still sustain, any data that we have, if we are to dose skip or dose modify, are we compromising any efficacy there?